Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Acceptability of HPV-self Sampling

NCT03137563CompletedOBSERVATIONAL

Summary

This trial aimed at evaluating the acceptability of HPV self-sampling among french women eligible for cervical cancer screening (25 - 65 years old) in the region of Occitanie, in the south of France. Acceptability will be evaluated using an anonymous questionnaire and the main outcome of the study will be the response acceptability " yes " or " no " for HPV self-sampling. Secondary outcome will be analysis of socioeconomic determinants for the acceptability of HPV self-sampling. These data will help to propose new strategies for cervical cancer screening in France, particularly to taget non-attenting populations

Key Facts

Lead Sponsor

University Hospital, Montpellier

Enrollment

356

Start Date

2017-05-15

Completion Date

2017-07-30

Study Type

OBSERVATIONAL

Official Title

Evaluation of the Acceptability of HPV Self-sampling Among French Women Eligible for Cervical Cancer Screening

Interventions

questionnaire

Conditions

Cervical Cancer

Eligibility

Age Range

25 Years – 65 Years

Sex

FEMALE

Inclusion Criteria:

* Women 25-65 years old
* Living in the Aude or Herault departments
* Informed patient Exclusion criteria
* Virgins
* Previous hysterectomy
* Present or previous cervical pathology
* Patient under guardianship or tutorship

Outcome Measures

Primary Outcomes

accept HPV self-sampling for cervical cancer

Response " Yes " or " No " to the question " would you accept HPV self-sampling for cervical cancer screening ?

Time frame: 1 day

Secondary Outcomes

Socioeconomic determinants of the response

Socioeconomic determinants of the response " yes " or " no " to the question " would you accept HPV self-sampling for cervical cancer screening ?

Time frame: 1 day

Locations

Uhmontpellier, Montpellier, France

Linked Papers

2020-10-26

Acceptability of vaginal self-sampling with high-risk human papillomavirus testing for cervical cancer screening: a French questionnaire-based study

In France, cervical cancer screening based on cervical smear has a participation rate of around 60%. New screening strategies are encouraged to increase the participation of under-screened women, including vaginal self-sampling with high-risk human papillomavirus (HR-HPV) testing. This study was based on the distribution of an anonymous self-administered questionnaire to assess the acceptability of vaginal self-sampling with HR-HPV testing by women aged 25 to 65 years in two French Departments of the South of France, Aude, and Hérault, showing low participation in cervical cancer screening. Factors influencing this acceptability were also analyzed. From May to July 2017, 349 completed questionnaires were collected. Women declared high acceptability for vaginal self-sampling (81%) preferably at home (82.6%). Acceptability was statistically higher in the Department of Herault (

Linked Investigators

Nathalie Boulle